Erratum: Subgroup analysis of the AFTER I-O study: A retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma (Japanese Journal of Clinical Oncology (2021) DOI: 10.1093/jjco/hyab114)

Yoshihiko Tomita, Go Kimura, Satoshi Fukasawa, Kazuyuki Numakura, Yutaka Sugiyama, Kazutoshi Yamana, Sei Naito, Hirokazu Kaneko, Yohei Tajima, Mototsugu Oya

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the originally published article there were errors in the legends to figures 3 and 4. Figure 3 should read: "Figure 3. PFS2 of nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) PFS2 of NIVO, stratified by TT regimens after NIVO, sunitinib, or axitinib. (b) PFS2 of NIVO+IPI, stratified by TT regimens after NIVO+IPI, sunitinib, or axitinib, IMDC all risks." instead of: "Figure 3.OS from first-line therapy of patients treated with nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) OS from first-linetherapy of patients treated with NIVO, stratified by TT regimens after NIVO, sunitinib or axitinib. (b) OS from first-line therapy of patients treated with NIVO+IPI,stratified by TT regimens after NIVO+IPI, sunitinib or axitinib, IMDC all risks.". Figure 4 should read: "Figure 4. OS from first-line therapy of patients treated with nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) OS from first-linetherapy of patients treatedwithNIVO, stratified by TT regimens afterNIVO, sunitinib or axitinib. (b) OS from first-line therapy of patients treated with NIVO+IPI,stratified by TT regimens after NIVO+IPI, sunitinib or axitinib, IMDC all risks." instead of: "Figure 4. PFS2 of nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) PFS2 of NIVO, stratified by TT regimens after NIVO, sunitinib, or axitinib. (b) PFS2 of NIVO+IPI, stratified by TT regimens after NIVO+IPI, sunitinib, or axitinib, IMDC all risks.". These errors have now been corrected online.

Original languageEnglish
Pages (from-to)1770
Number of pages1
JournalJapanese journal of clinical oncology
Volume51
Issue number12
DOIs
Publication statusPublished - 2021 Dec 1

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'Erratum: Subgroup analysis of the AFTER I-O study: A retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma (Japanese Journal of Clinical Oncology (2021) DOI: 10.1093/jjco/hyab114)'. Together they form a unique fingerprint.

Cite this